Clinical Trials Logo

X-Linked Protoporphyria clinical trials

View clinical trials related to X-Linked Protoporphyria.

Filter by:
  • None
  • Page 1

NCT ID: NCT05020184 Recruiting - Clinical trials for Erythropoietic Protoporphyria

Effect of Oral Cimetidine in the Protoporphyrias

Start date: June 14, 2022
Phase: Phase 2
Study type: Interventional

Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) result from genetic defects of heme biosynthesis that cause life-long, painful cutaneous sensitivity to light. The objective of this study is to determine the efficacy and safety of oral cimetidine administration for treatment of the protoporphyrias. Efficacy will be based on protoporphyrin levels, photosensitivity, and quality of life questionnaires. Funding Source- FDA OOPD

NCT ID: NCT02979249 Completed - Clinical trials for Erythropoietic Protoporphyria

Oral Iron for Erythropoietic Protoporphyrias

EPP
Start date: December 2016
Phase: N/A
Study type: Interventional

In the medical literature there are conflicting reports on whether iron improves symptoms in patients with EPP and XLP. Giving iron to people who are iron deficient is thought to improve EPP symptoms. However, this has never been systematically tested. Therefore, the purpose of this study is to determine the effect of oral iron for EPP and XLP patients.

NCT ID: NCT01688895 Completed - Clinical trials for Erythropoietic Protoporphyria

Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact

Start date: July 2012
Phase:
Study type: Observational

The initial objective of this protocol is to assemble a well-documented group of patients with confirmed diagnoses of the erythropoietic protoporphyrias, including autosomal recessive Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) for clinical, biochemical, and genetic studies. The long-term objectives are (1) to conduct a longitudinal investigation of the natural history, complications, and therapeutic outcomes in people with erythropoietic protoporphyria, (2) to systematically investigate the psychological effects of the erythropoietic protoporphyrias on children and adults, and (3) to investigate the correlation between the identified genotypes and the resulting clinical presentation, also determining the possible interaction of other genetic markers.